SCHEMBL10150337

SCHEMBL10150337

CC1CCc2nc(-c3ccccc3O)nc(N3CCC(C(F)(F)F)C3)c2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 4/20 0.43
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 5/20 0.41
MAPT P10636 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMAD3 P84022 1/20 0.36
ADORA2A P29274 1/20 0.35
HPGD P15428 3/20 0.35
ADORA1 P30542 1/20 0.35
HSD17B10 Q99714 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
ACHE P22303 1/20 0.34
TNKS O95271 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150311 0.92 CHEK2 (0.43) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL12527321 0.87 CHEK2 (0.43) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL10150324 0.85 ALDH1A1 (0.53) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL10150318 0.83 SMAD3 (0.53) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL10150319 0.82 SMAD3 (0.52) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL10150326 0.81 MEN1 (0.57) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL10150322 0.81 PIK3CA (0.52) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL8297579 0.77 ALDH1A1 (0.53) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL10150299 0.77 ALDH1A1 (0.53) CHEK2KDM4EALDH1A1MAPTTDP1
SCHEMBL8297581 0.76 SMAD3 (0.44) CHEK2KDM4EALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 CHEK2 3657/4885KDM4E 2477/4885ALDH1A1 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.